Skip to content Skip to sidebar Skip to footer

Lumos Diagnostics (ASX: LDX) Falls Despite FDA Win- Here’s Why the Dip Could Be a Buying Opportunity

Lumos Diagnostics Falls After FDA Waiver Lumos Diagnostics (ASX: LDX) slipped around 3.8% on Friday despite announcing one of the most important milestones in its history. The US Food and…

ByUjjwal Maheshwari

Jan 2026

Biotech Stocks

Neuren Pharmaceuticals (ASX:NEU) Surges 6% on US$700m DAYBUE Target: Time to Buy?

DAYBUE royalties could climb fast if US targets land Neuren Pharmaceuticals (ASX: NEU) jumped 6% on Wednesday after its US partner, Acadia Pharmaceuticals, shared big news at the J.P. Morgan…

ByUjjwal Maheshwari

Jan 2026

Biotech Stocks

NeuroScientific (ASX:NSB) Reports 75% Response Rate in Crohn’s Trial: Is This Stem Cell Stock a Buy?

NeuroScientific jumps on early Crohn’s stem cell results NeuroScientific Biopharmaceuticals (ASX: NSB) surged 43% on Tuesday after announcing promising early results from its stem cell program. Three out of four patients…

ByUjjwal Maheshwari

Jan 2026

Biotech Stocks

Island Pharmaceuticals (ASX:ILA) Surges 12% on US Patent Win: Speculative Buy or Too Risky?

Island Pharmaceuticals Secures US Patent for Galidesivir Island Pharmaceuticals (ASX: ILA) jumped 12 per cent this week after announcing it secured a US patent for galidesivir, its antiviral drug designed…

ByUjjwal Maheshwari

Dec 2025

Biotech Stocks

Mesoblast (ASX:MSB) Reaches Multi-Year High as Ryoncil Revenue Targets US$30M: Is It Still a Buy?

Commercial momentum builds as Mesoblast targets two major 2026 catalysts: Adult label expansion and Revascor BLA filing. Mesoblast (ASX: MSB) closed at A$2.91 last Friday, up 27% over the past…

ByUjjwal Maheshwari

Dec 2025

Biotech Stocks

Recce Pharmaceuticals (ASX: RCE) Secures A$85M R&D Backing: Is It a Buy Before Phase 3 Results?

Recce secures A$85m R&D backing as Phase 3 nears Recce Pharmaceuticals (ASX: RCE) hit a one-week high after landing an A$85 million Advanced Overseas Finding from AusIndustry. This ruling is…

ByUjjwal Maheshwari

Dec 2025

Biotech Stocks

Neurizon (ASX:NUZ) Clears FDA Hurdle for ALS Trial- Speculative Buy at 75% Off Highs?

Neurizon Therapeutics (ASX: NUZ) just hit a major milestone. The FDA has cleared its lead drug NUZ-001 to enter the HEALEY ALS Platform Trial at Massachusetts General Hospital, with patients…

ByUjjwal Maheshwari

Dec 2025

Biotech Stocks

Race Oncology Raises $3.2m at 6% Premium: Is RAC Still a Buy After 87% Rally?

Race Oncology’s (ASX: RAC) latest capital raise sends a strong signal. The company secured A$3.2 million from sophisticated investors at $2.83 per share, a 6% premium to its last close.…

ByUjjwal Maheshwari

the Kick-ass Multipurpose WordPress Theme

Lumos Diagnostics (ASX: LDX) Falls Despite FDA Win- Here’s Why the Dip Could Be a Buying Opportunity

Neuren Pharmaceuticals (ASX:NEU) Surges 6% on US$700m DAYBUE Target: Time to Buy?

NeuroScientific (ASX:NSB) Reports 75% Response Rate in Crohn’s Trial: Is This Stem Cell Stock a Buy?

Island Pharmaceuticals (ASX:ILA) Surges 12% on US Patent Win: Speculative Buy or Too Risky?

Mesoblast (ASX:MSB) Reaches Multi-Year High as Ryoncil Revenue Targets US$30M: Is It Still a Buy?

Recce Pharmaceuticals (ASX: RCE) Secures A$85M R&D Backing: Is It a Buy Before Phase 3 Results?

Neurizon (ASX:NUZ) Clears FDA Hurdle for ALS Trial- Speculative Buy at 75% Off Highs?

Race Oncology Raises $3.2m at 6% Premium: Is RAC Still a Buy After 87% Rally?

Investing in the Year of the Rat

2020, the Golden Year

Market trouble spots to avoid in 2020

Add Your Heading Text Here